Is BMD testing appropriate for all menopausal women?

International Journal of Fertility and Women's Medicine

Volumn 50, Issue 2, 2005, Pages 61-66

  Kleerekoper, Michael ^a,b   Nelson, Dorothy A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Endocrine Division   (United States)

Author keywords

Risk factors (osteoporosis); T score; WHO guidelines; Z score

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; HEPARIN; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THYROXINE;

BONE DENSITOMETRY; BONE MASS; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED PRACTICE; FALLING; HEMOGLOBINOPATHY; HUMAN; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; WOMEN'S HEALTH; AGED; BONE DENSITY; EPIDEMIOLOGY; FEMALE; METABOLISM; MIDDLE AGED; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; RADIODENSITOMETRY; REPRODUCIBILITY; RISK FACTOR; UNITED STATES;

AGED; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SELECTION BIAS; UNITED STATES; WOMEN'S HEALTH;

EID: 33644684274     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Org Tech Rep Sci 843:1-129, 1994.
2. U.S. Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 137(6):526-528, 2002.
3. Nelson HD, Helfand M, Woolf SH, et al: Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(6):529-541, 2002.
4. Nelson DA, Molloy R, Kleerekoper M: Prevalence of osteoporosis in women referred for bone density testing: utility of multiple skeletal sites. J Clin Densitom 1(1):5-12, 1998.
5. Albrand G, Munoz F, Sornay-Rendu E, et al: Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78-85, 2003.
6. www.nof.org
7. www.aace.com
8. www.nlm.nih.gov/pubs/cbm/osteopomsis.html
9. www.biomedcentral.com
10. Sorkin JD, Muller DC, Andres R: Longitudinal change in height of men and women: implications for interpretation of the body mass index: the Baltimore Longitudinal Study of Aging. Am J Epidemiol 150(9):969-977, 1999.
11. Manns RA, Haddaway MJ, McCall IW, et al: The relative contribution of disc and vertebral morphometry to the angle of kyphosis in asymptomatic subjects. Clin Radiol 51(4):258-262, 1996.
12. Nicholson PH, Haddaway MJ, Davie MW, et al: Vertebral deformity, bone mineral density, back pain and height loss in unscreened women over 50 years. Osteoporos Int 3(6):300-307, 1993.
13. van Leer EM, van Noord PA, Seidell JC: Components of adult height and height loss. Secular trend and effects of aging in women in the DOM project. Ann Epidemiol 2(5):611-615, 1992.
14. Galloway A, Stini WA, Fox SC, et al: Stature loss among an older United States population and its relation to bone mineral status. Am J Phys Anthropol 83(4):467-476, 1990.
15. Garnero P, Sornay-Rendu E, Duboeuf F, et al: Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14(9):1614-1621, 1999.
16. Anderson GL, Limacher M, Assaf AR, et al: Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14):1701-1712, 2004.
17. Cauley JA, Robbins J, Chen Z, et al: Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290(13):1729-1738, 2003.
18. Setchell KD, Lydeking-Olsen E: Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 78(3 Suppl):593S-609S, 2003.
19. Gallagher JC, Satpathy R, Rafferty K, et al: The effect of soy protein isolate on bone metabolism. Menopause 11(3):290-298, 2004.
20. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276(17):1404-1408, 1996.
21. Lucas FL, Cauley JA, Stone RA, et al: Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am J Epidemiol 148(1): 22-29, 1998.
22. Nguyen TV, Center JR, Eisman JA: Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. Maturitas 36(1):27-34, 2000.
23. Zmuda JM, Cauley JA, Ljung BM, et al: Study of Osteoporotic Fractures Research Group: Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst 93(12):930-936, 2001.
24. van der Klift M, de Laet CE, Coebergh JW, et al: Bone mineral density and the risk of breast cancer. Bone 32(3):211-216, 2003.
25. Nelson DA, Darga LL, Simon MS, et al: Radial bone density and breast cancer risk in white and African-American women. Osteoporos Int 15:535-540, 2004.
26. Tannenbaum C, Clark J, Schwartzman K, et al: Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87(10):4431-4437, 2002.
27. Lundgren E, Rastad J, Thrufjell E, et al: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287-294, 1997.
28. Silverberg SJ, Bilezikian JP: "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 88(11):5348-5352, 2003.
29. Maruani G, Hertig A, Paillard M, et al: Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641-4648, 2003.
30. Khan AA, Bilezikian JP, Kung AW, et al: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(7):3319-3325, 2004.